Based mainly on work on melanomas, it has been proposed that the TME of tumours can be classified based on their presence or absence of TILs and expression of PD-L1, with a view to rational design and prediction of response to PD-1/PD-L1 ICB immunotherapy for cancer patients [177]. The gene discussed is PDCD1; the disease is cancer.